Definium Therapeutics, Inc. (DFTX)
NASDAQ:DFTX
Want to see DFTX full AI Analyst Report?
DFTX Stock Chart & Stats
$22.68
-$0.97(-11.96%)
At close: 4:00 PM EST
$22.68
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$6.35 - $26.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.97M
Market Cap
$2.67B
Enterprise Value$2.40B
Total Cash (Recent Filing)$373.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding109,066,780
10 Day Avg. Volume2,323,154
30 Day Avg. Volume1,970,905
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.80
Forecast
1Y Price Target
$51.00Price Target Upside124.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity / RunwayA cash and investment position of $373.4M that management says funds operations into 2028 provides durable optionality to complete multiple Phase III readouts and invest in commercial preparedness. This reduces near-term financing pressure and gives time to validate clinical outcomes before major capital raises.
Late-stage Clinical Program With Multiple Pivotal ReadoutsHaving three staggered pivotal readouts across MDD and GAD concentrates structural value-creation in a defined timeline. High statistical power in key studies and Breakthrough Therapy designation in GAD increase the likelihood that positive data will support regulatory discussions and reduce binary failure risk compared with single-study programs.
Low Leverage / Debt-free Balance SheetA zero-debt capital structure with a meaningful equity base preserves financial flexibility and limits fixed obligations. This durable strength supports continued R&D and commercialization investments without immediate refinancing risk, making balance-sheet-driven distress unlikely over the next several quarters.
Bears Say
Pre-revenue Status With Widening LossesThe company remains pre-revenue with accelerating net losses (TTM roughly -$237.5M). Over the medium term this means operational viability is tied to trial success or fresh capital; persistent losses erode equity and increase the probability of dilutive financings if clinical or regulatory timelines slip.
Negative And Worsening Operating Cash FlowConsistently negative operating cash flow, worsening to roughly -$143.7M TTM, signals structural cash burn driven by R&D and commercialization buildout. This trend increases reliance on external funding and limits the firm’s ability to scale commercial operations without additional capital, a material medium-term constraint.
Clinical Design/placebo And Regulatory/commercial UncertaintyA high placebo response in Phase II and design-related risks create a durable execution risk for pivotal readouts; coupled with outstanding regulatory, payer, and coding questions, these issues can materially delay approvals or limit label and reimbursement, constraining commercial uptake even with positive efficacy signals.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics, Inc.’s price range in the past 12 months?
Definium Therapeutics, Inc. lowest stock price was $6.34 and its highest was $26.25 in the past 12 months.
What is Definium Therapeutics, Inc.’s market cap?
Definium Therapeutics, Inc.’s market cap is $2.67B.
When is Definium Therapeutics, Inc.’s upcoming earnings report date?
Definium Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 45 days.
How were Definium Therapeutics, Inc.’s earnings last quarter?
Definium Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.492 by -$0.218.
Is Definium Therapeutics, Inc. overvalued?
According to Wall Street analysts Definium Therapeutics, Inc.’s price is currently Undervalued.
Does Definium Therapeutics, Inc. pay dividends?
Definium Therapeutics, Inc. does not currently pay dividends.
What is Definium Therapeutics, Inc.’s EPS estimate?
Definium Therapeutics, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Definium Therapeutics, Inc. have?
Definium Therapeutics, Inc. has 109,066,780 shares outstanding.
What happened to Definium Therapeutics, Inc.’s price movement after its last earnings report?
Definium Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.492. Following the earnings report the stock price went down -4.957%.
Which hedge fund is a major shareholder of Definium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.00 (124.87% Upside)
$51.00 (124.87% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
245.27%
12-Months-Change
Fundamentals
Return on Equity
-102.48%
Trailing 12-Months
Asset Growth
45.75%
Trailing 12-Months
Company Description
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
DFTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DFTX earnings summariesDFTX Stock 12 Month Forecast
Average Price Target
$51.00
▲(124.87% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.66% Insiders
9.04% Mutual Funds
34.53% Other Institutional Investors
46.14% Public Companies and Individual Investors